Celldex Therapeutics Inc [CLDX] stock is trading at $17.79, up 5.64%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLDX shares have gain 13.10% over the last week, with a monthly amount drifted -12.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on March 20, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $46. Previously, UBS started tracking the stock with Buy rating on February 13, 2025, and set its price target to $44. On October 07, 2024, Citigroup initiated with a Buy rating and assigned a price target of $70 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $45 on September 30, 2024. Wolfe Research downgraded its rating to a Peer Perform. Stifel started tracking with a Buy rating for this stock on June 18, 2024, and assigned it a price target of $58. In a note dated June 11, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $51 on this stock.
Celldex Therapeutics Inc [CLDX] stock has fluctuated between $14.40 and $47.00 over the past year. Currently, Wall Street analysts expect the stock to reach $63 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $17.79 at the most recent close of the market. An investor can expect a potential return of 254.13% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Celldex Therapeutics Inc [NASDAQ:CLDX] reported sales of 7.02M for the trailing twelve months, which represents a drop of -71.56%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -27.79%, Pretax Profit Margin comes in at -22.49%, and Net Profit Margin reading is -22.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.2 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.02 points at the first support level, and at 16.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.29, and for the 2nd resistance point, it is at 18.78.
Ratios To Look Out For
For context, Celldex Therapeutics Inc’s Current Ratio is 18.91. Further, the Quick Ratio stands at 18.91, while the Cash Ratio is 0.72. Considering the valuation of this stock, the price to sales ratio is 168.22, the price to book ratio is 1.58.
Transactions by insiders
Recent insider trading involved Marucci Anthony S, PRESIDENT & CEO, that happened on Nov 11 ’24 when 11500.0 shares were purchased. SVP AND CFO, Martin Samuel Bates completed a deal on Jun 14 ’24 to sell 17172.0 shares. Meanwhile, SR. VP & CPDO Crowley Elizabeth sold 30000.0 shares on Jun 14 ’24.
